mavrostobart + docetaxel

Mavrostobart + docetaxel is a combination therapy consisting of **mavrostobart** (PT199), an anti-CD73 monoclonal antibody, and **docetaxel**, a small molecule chemotherapy agent. **Mavrostobart** inhibits both soluble and membrane-bound CD73 enzyme, countering the adenosine-mediated immunosuppressive tumor microenvironment and increasing antitumor immune activation. It offers full inhibition without “hook effect” at higher concentrations, overcoming limitations of other CD73 antibodies.[1][2][5][6] **Docetaxel** is a cytotoxic taxane that stabilizes microtubules and induces cell cycle arrest and apoptosis in dividing cells.[3][7] In combination, mavrostobart enhances immune activation while docetaxel exerts direct cytotoxic effects on tumor cells. The combination as investigated in the MORNINGSTAR (NCT05431270) clinical study is being used to evaluate safety, efficacy, and immune activation in advanced malignancies, with particular focus on solid tumors expressing high levels of CD73.[1][2][4][5][6]

Other names

mavrostobartPT199PT-199PT 199mavrostobart + docetaxel